

ASX RELEASE**8 March 2022****ASX: NVU**

Nanoshield Files Registration as a Medical Device in the UK

Highlights:

- **Nanoshield™ Antiviral Film product filed as Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA).**
- **As a Class I medical device, Nanoshield™ is able to be marketed with immediate effect for a broader range of medical applications.**
- **Registration builds further international momentum and strengthens the capabilities of exclusive UK distributor partner, CuVira.**
- **Nanoshield™ is the only self-disinfecting coating registered as a Class 1 medical device in the UK.**

Nanoveu Limited (**ASX:NVU**) ("**Nanoveu**" or the "**Company**") is pleased to announce that the Company has applied for registration of its Nanoshield™ Film line as a Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) for the UKCA (UK Conformity Assessed) Mark.

The Nanoshield™ product, which is a protective film employing a transparent resin with activated copper exhibiting antimicrobial and antiviral properties, will now be able to be marketed for a range of medical and non-medical applications in the United Kingdom.

Commenting on the submission Nanoveu's Managing Director and CEO, Alfred Chong, said:

"Nanoveu continues to support its Nanoshield product in a range of international markets and is exceptionally pleased that it has been filed for registration as a Class I medical device in the UK. This is important as it enhances the reach of our products, but also builds confidence amongst end users that Nanoshield is accepted in major markets such as the UK. The registration quickly follows similarly positive regulatory news with the product receiving EPA Approval in the USA¹."

"By any measure, the UK is one of the largest healthcare markets, with the UK's National Health Service being one of the world's largest employers, and the nation is also home to a number of other major health organisations. Given its global significance, the UK is an important target for Nanoveu."

"Nanoveu will continue to make regulatory submissions to key medical markets across the globe and will endeavour to keep shareholders updated as further progress is made."

Nanoshield is intended to be applied to high touch surfaces of medical devices including, but not limited to, display screens of defibrillators and imaging devices to provide long lasting, continuous disinfection, reducing user-to-user touch cross-contamination thus assisting in prevention of

¹ See announcement of 6 May 2021

disease. The applications within the medical context can also include touch screens, handrails, trolleys, wheel chair handles and just about any high touch point.

Nanoveu is well placed to enhance sales under the UKCA Mark, with the Company having executed an exclusive distribution agreement within the region with CuVira Limited² in 2021.

CuVira is a recently established venture with strong links throughout the UK, particularly in the commercial and construction sectors.

As the UK economy opens, Nanoshield is well poised to provide a passive way of defending consumers against the virus.

Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the inactivation of viruses and bacteria. The technology has been proven to eliminate 99.99% of SARS-CoV-2 (COVID-19) and HCoV-299E, OC43, another coronavirus affecting humans in 30 minutes³.

In addition to SARS-CoV-2 (COVID-19) and HCoV-299E, Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the inactivation of other viruses. The technology has been proven to eliminate 99.99%⁴ of OC43, another coronavirus affecting humans in 30 minutes. The antiviral protection has also been validated against other bacteria and viruses including E. coli, Influenza A (subtype H3N2), and coronavirus MHV-A59⁵. Additionally, testing simulating 12 months outdoor weather exposure has found Nanoveu's film products retain their effectiveness against MS2 Bacteriophage, a single-strand RNA virus⁶.

- Ends -

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Alfred Chong
Managing Director and CEO

t: +65 6557 0155

e: info@nanoveu.com

For media / investor enquiries, please contact:

Jane Morgan
Investor Relations

t: 0405 555 618

e: info@janemorganmanagement.com.au

² See announcement of 15 February 2021

³ See announcement of 28 July 2021

⁴ See announcements of 5 and 25 May 2020

⁵ See announcement of 15 April 2020

⁶ See ASX announcement of 18 February 2021



About Nanoveu Limited

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

Nanoshield - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.